merck - Search News

News

Merck KGaA, SpringWorks

Germany's Merck says in late-stage discussions to buy SpringWorks for $3.5 billion

Germany's Merck KGaA said on Thursday it is in late-stage talks to acquire U.S.-based SpringWorks Therapeutics for about $3.5 billion, a deal that could give it access to a recently approved rare disease drug and expand its portfolio of experimental cancer treatments.

GlobalData on MSN · 12h

Merck KGaA nears $3.5bn deal for SpringWorks

Merck KGaA has confirmed that it is in late-stage discussions with SpringWorks, valuing the deal at a price of around $47 per share.

BioSpace · 17h

SpringWorks Surges on Potential $3.5B Merck KGaA Buyout

The transaction, which sources say could be agreed upon as soon as Monday, would price SpringWorks at $47 per share, totaling approximately $3.5 billion for the acquisition.

Merck, expected tariff

The Wall Street Journal on MSN · 1d

Merck Cuts 2025 Outlook on Tariffs, Charges

Merck’s first-quarter net income increased as sales of its Keytruda cancer drug rose, but the Big Pharma company cut its 2025 adjusted earnings projection, partly to account for recently imposed tariffs.

Reuters on MSN · 1d

Merck Posts Higher Profit, Puts Tariffs Cost at $200 Million

For 2025, Merck said it still expects sales of $64.1 billion to $65.6 billion, but it lowered its adjusted earnings per share forecast to between $8.82 and $8.97, from a previous $8.88 to $9.03. Analysts have forecast 2025 earnings of $8.95 per share on revenue of $65 billion.

CNBC on MSN · 1d

Merck lowers profit outlook, partly due to $200 million expected tariff hit

Merck said the expected tariff charge primarily reflects levies between the U.S. and China, but does not account for Trump’s planned pharmaceutical tariffs.

Merck Faces Lawsuit to Block Launch of Easier-to-Use Keytruda

A biotech company is suing to block Merck & Co. from launching an easier-to-use version of its blockbuster cancer treatment ...

STAT14h

Akeso wins Chinese approval for cancer drug positioned to rival Merck’s Keytruda

Akeso, a Chinese biotech that made headlines for beating Merck’s Keytruda in a head-to-head trial, won approval in China this week for the therapy, a company spokesperson confirmed to STAT. New data ...

10h

Merck Stays Confident On M&A Despite Market Uncertainty: Analyst

Merck projects $200 million in tariff costs, boosts U.S. manufacturing plans, and continues M&A efforts amid external pressures and shifting market dynamics.

pharmaphorum21h

Merck puts a price on its SpringWorks takeover bid

So far, SpringWorks – which was spun out of Pfizer in 2017 and has recently received FDA approval for a second therapy for a ...

19h

Halozyme sues Merck; FDA blames cuts for Vanda delay

Halozyme claims Merck infringed on patents in developing a subcutaneous form of Keytruda. Elsewhere, Vanda’s challenge to an ...

17h

Merck price target lowered to $82 from $89 at BMO Capital

BMO Capital analyst Evan Seigerman lowered the firm’s price target on Merck (MRK) to $82 from $89 and keeps a Market Perform rating on the ...

STAT16h

Pharmalittle: We’re reading about the FDA and revolving doors, a Novo win over compounders, and more

Scores of FDA employees are searching for an exit from an agency in turmoil, especially staffers tasked with reviewing drug ...

16h

Dow's 117-point drop led by losses in Merck, Verizon shares

Shares of Merck and Verizon are retreating Friday morning, sending the Dow Jones Industrial Average into negative territory.

Results that may be inaccessible to you are currently showing.

Hide inaccessible results

News

Merck KGaA, SpringWorks

Merck, expected tariff

Related topics